NONMEM Users Network Archive

Hosted by Cognigen

Re: [NMusers] ASCO and pharmacometrics

From: Sharma, Manish R. [MED] <msharma_at_bsd.uchicago.edu>
Date: Wed, 6 Apr 2016 04:29:06 +0000

Hi Naoto,

I am a clinical oncologist and I attend ASCO every year. I had a poster la=
st year that was reporting our model of chemotherapy-induced peripheral neu=
ropathy and the results of simulations to determine a dose-adjustment algor=
ithm.

I think it is likely that your work was underappreciated by the scientific =
review committee. Unlike the ACoP and ASCPT meetings, many reviewers would =
be unfamiliar with pharmacometrics.

As a community, we should continue submitting our work to these types of me=
etings, but I would recommend focusing on the clinical and/or drug developm=
ent decisions that were supported by the model rather than the technical de=
tails.

Best regards,

Manish Sharma, MD

On Apr 5, 2016, at 8:44 PM, Naoto Hayashi <neohayashi_at_gmail.com<mailto:neoh=
ayashi_at_gmail.com>> wrote:


Dear all,

I have a question and appreciate it if somebody can answer to me.

We had submitted an abstract to ASCO annual meeting presentation 2016, and =
its contents included a pharmacometrics work of quantitative safety profile=
 analysis of an anticancer drug. The behave of the safety index time cours=
es is very unique and its results showed a very high usefulness of this dru=
g. The abstract also included the table of population PK/PD parameters tha=
t expressed its nature, and it was compared with the similar older drug saf=
ety profile and demonstrated very high safer profile quantitatively.

I have some experiences to publish some articles of population PK/PD work i=
n several clinical pharmacology journals in the past, and I was so confiden=
t for just a poster presentation in ASCO. However, the judgment was “pub=
lication only”, i.e. just presentation in online but no poster presentati=
on and no official record of publication officially.

So, my question is whether pharmacometrics work is difficult to be picked u=
p in ASCO presentation. Or, was my work evaluated to have no worth to be p=
resented even in poster session because the pharmacometrics works presented=
 in ASCO are having very high level?

I have never visited ASCO before, and I just want to hear opinions about ho=
w much of importance is considered for pharmacometrics work in ASCO.

Thanks a lot in advance for your comments/thoughts.

Best regards,
Naoto Hayashi

***************************************************************************=
*****
This e-mail is intended only for the use of the individual or entity to whi=
ch
it is addressed and may contain information that is privileged and confiden=
tial.
If the reader of this e-mail message is not the intended recipient, you are=
 
hereby notified that any dissemination, distribution or copying of this
communication is prohibited. If you have received this e-mail in error, ple=
ase
notify the sender and destroy all copies of the transmittal.

Thank you
University of Chicago Medicine and Biological Sciences
***************************************************************************=
*****
Received on Wed Apr 06 2016 - 00:29:06 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: nmusers-request_at_iconplc.com. Once subscribed, you may contribute to the discussion by emailing: nmusers@globomaxnm.com.